The Francis Crick Institute
1-s2.0-S2162253120303930-main (1).pdf (1.57 MB)

Engineering of human induced pluripotent stem cells via human artificial chromosome vectors for cell therapy and disease modeling

Download (1.57 MB)
journal contribution
posted on 2021-02-04, 14:27 authored by Yasuhiro Kazuki, Narumi Uno, Satoshi Abe, Naoyo Kajitani, Kanako Kazuki, Yuwna Yakura, Chiaki Sawada, Shuta Takata, Masaki Sugawara, Yuichi Nagashima, Akane Okada, Masaharu Hiratsuka, Mitsuhiko Osaki, Giulia Ferrari, Francesco Saverio Tedesco, Satoshi Nishikawa, Ken Fukumoto, Shin-ichiro Takayanagi, Atsushi Kunisato, Shin Kaneko, Mitsuo Oshimura, Kazuma Tomizuka
© 2020 The Authors Genetic engineering of induced pluripotent stem cells (iPSCs) holds great promise for gene and cell therapy as well as drug discovery. However, there are potential concerns regarding the safety and control of gene expression using conventional vectors such as viruses and plasmids. Although human artificial chromosome (HAC) vectors have several advantages as a gene delivery vector, including stable episomal maintenance and the ability to carry large gene inserts, the full potential of HAC transfer into iPSCs still needs to be explored. Here, we provide evidence of a HAC transfer into human iPSCs by microcell-mediated chromosome transfer via measles virus envelope proteins for various applications, including gene and cell therapy, establishment of versatile human iPSCs capable of gene loading and differentiation into T cells, and disease modeling for aneuploidy syndrome. Thus, engineering of human iPSCs via desired HAC vectors is expected to be widely applied in biomedical research.


Usage metrics

    The Francis Crick Institute


    Ref. manager